Literature DB >> 21471482

Preventing bloodstream infections: a measurable national success story in quality improvement.

Peter J Pronovost1, Jill A Marsteller, Christine A Goeschel.   

Abstract

Over the past decade, advances in the quality of care have been slow. One area of success, however, has been in combating central line-associated bloodstream infections. Data from the Centers for Disease Control and Prevention suggest that the number of patients in US intensive care units suffering a central-line infection declined by 63 percent between 2001 and 2009. We describe the multistep process taken by many stakeholders-states, federal agencies, hospital associations, regulatory and nonprofit associations, clinicians, and local hospitals-to collaborate on the successful reduction and eradication of these infections. Having begun in Michigan, this program has spread to forty-five states, has shown sustained results in reducing hospital-associated infections and mortality, and constitutes an important measurable national success story in quality improvement and a model for improving the health and safety of Americans.

Entities:  

Mesh:

Year:  2011        PMID: 21471482     DOI: 10.1377/hlthaff.2011.0047

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  24 in total

1.  State-Mandated Hospital Infection Reporting Is Not Associated With Decreased Pediatric Health Care-Associated Infections.

Authors:  Michael L Rinke; David G Bundy; Fizan Abdullah; Elizabeth Colantuoni; Yiyi Zhang; Marlene R Miller
Journal:  J Patient Saf       Date:  2015-09       Impact factor: 2.844

2.  Bringing central line-associated bloodstream infection prevention home: CLABSI definitions and prevention policies in home health care agencies.

Authors:  Michael L Rinke; David G Bundy; Aaron M Milstone; Kristin Deuber; Allen R Chen; Elizabeth Colantuoni; Marlene R Miller
Journal:  Jt Comm J Qual Patient Saf       Date:  2013-08

3.  Ensuring that guidelines help reduce patient harm.

Authors:  Peter J Pronovost
Journal:  J Oncol Pract       Date:  2013-02-05       Impact factor: 3.840

4.  A new frontier: Central line-associated bloodstream infection surveillance in home infusion therapy.

Authors:  Sara C Keller; Deborah Williams; Clare Rock; Shiv Deol; Polly Trexler; Sara E Cosgrove
Journal:  Am J Infect Control       Date:  2018-06-13       Impact factor: 2.918

5.  Establishing standard hospital performance measures for cervical spinal trauma: a Nationwide In-patient Sample study.

Authors:  D J Hoh; M Rahman; K M Fargen; D Neal; B L Hoh
Journal:  Spinal Cord       Date:  2015-10-20       Impact factor: 2.772

6.  Vascular Access Tracking System: a Web-Based Clinical Tracking Tool for Identifying Catheter Related Blood Stream Infections in Interventional Radiology Placed Central Venous Catheters.

Authors:  James Morrison; John Kaufman
Journal:  J Digit Imaging       Date:  2016-12       Impact factor: 4.056

7.  Value of Public Health Funding in Preventing Hospital Bloodstream Infections in the United States.

Authors:  Melanie D Whittington; Cathy J Bradley; Adam J Atherly; Jonathan D Campbell; Richard C Lindrooth
Journal:  Am J Public Health       Date:  2017-09-21       Impact factor: 9.308

8.  Assessing burden of central line-associated bloodstream infections present on hospital admission.

Authors:  Hannah Leeman; Sara E Cosgrove; Deborah Williams; Sara C Keller
Journal:  Am J Infect Control       Date:  2019-09-09       Impact factor: 2.918

9.  Using Incentives to Improve Resource Utilization: A Quasi-Experimental Evaluation of an ICU Quality Improvement Program.

Authors:  David J Murphy; Peter F Lyu; Sara R Gregg; Greg S Martin; Jason M Hockenberry; Craig M Coopersmith; Michael Sterling; Timothy G Buchman; Jonathan Sevransky
Journal:  Crit Care Med       Date:  2016-01       Impact factor: 7.598

10.  Testing the Quality Health Outcomes Model Applied to Infection Prevention in Hospitals.

Authors:  Heather M Gilmartin; Karen H Sousa
Journal:  Qual Manag Health Care       Date:  2016 Jul-Sep       Impact factor: 0.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.